Hye Jin Yoo
Seoul, South Korea
NCT Number: NCT01100671
Vascular inflammation is a key factor in both the pathogenesis and outcome of atherosclerosis. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising tool for identifying and quantifying vascular inflammation within atherosclerotic plaques.cardiac multidetector-row CT can provide measurements of coronary artery calcium (CAC), the degree of stenosis, and the characteristics of plaque including its potential vulnerability. Therefore, the purpose of the investigators study is to compare the usefulness of 18 FDG-PET and MDCT in assessing the vascular inflammatory status and vulnerability.
Looking for future studies?
Notify Me20 year–80 year
All sexes
Observational
Seoul, South Korea
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This is not intervention study. The purpose of the study is to examine the relationship of vascular inflammation assessed by 18FDG-PET and MDCT at the cross section setting
Time frame: 20weeks
Time frame: 20 weeks
Korea University
Other
Comparison of 18F-fluorodeoxyglucose Positron Emission Tomography and Coronary Computed Tomography in Assessing Vascular Inflammation in Healthy Population
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05906797
Arterial Occlusive Diseases, Arteriosclerosis
Catania, Italy
View Trial DetailsNCT02991703
Arterial Occlusive Diseases, Arteriosclerosis
Nantes, France
View Trial DetailsNCT04167761
Arterial Occlusive Diseases, Arteriosclerosis
Stanford, California, United States
View Trial DetailsNCT02505399
Arterial Occlusive Diseases, Arteriosclerosis
Toulouse, Haute-Garonne, France
View Trial Details